Literature DB >> 17418538

Economic consequences of alternative medication strategies in first episode non-affective psychosis.

A D Stant1, E M TenVergert, L Wunderink, F J Nienhuis, D Wiersma.   

Abstract

BACKGROUND: Maintenance treatment appears to be successful in preventing relapses in first episode psychosis, but is also associated with side effects. Guided discontinuation strategy is a less intrusive intervention, but may lead to more relapses. In the current economic evaluation, costs and health outcomes of discontinuation strategy will be compared with the results of maintenance treatment in patients with remitted first episode psychosis.
METHOD: The study was designed as a randomised clinical trial. In total 128 patients were prospectively followed for 18 months after six months of stable remission. The economic evaluation was conducted from a societal perspective. Quality-adjusted life years (QALYs) were used as primary health outcome in the economic evaluation. Relapse rates were assessed in addition to various other secondary outcomes.
RESULTS: There were no relevant differences in mean costs between groups during the study. Total costs were largely influenced by costs related to admissions to psychiatric hospitals. No differences between groups were found for QALY results.
CONCLUSIONS: There were no indications that either of the examined interventions is superior to the other in terms of costs or QALY results. Additional results indicated that the relapse rate in discontinuation strategy was twice as high, but without an increase in hospital admissions or negative consequences on other clinical outcomes. For a minority of remitted first episode patients, guided discontinuation strategy may offer a feasible alternative to maintenance treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17418538     DOI: 10.1016/j.eurpsy.2007.02.003

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  6 in total

1.  Economic aspects of peer support groups for psychosis.

Authors:  A D Stant; S Castelein; R Bruggeman; J T van Busschbach; M van der Gaag; H Knegtering; D Wiersma
Journal:  Community Ment Health J       Date:  2009-03-24

2.  Does Non-Adherence Increase Treatment Costs in Schizophrenia?

Authors:  Mark Pennington; Paul McCrone
Journal:  Pharmacoeconomics       Date:  2018-08       Impact factor: 4.981

Review 3.  The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review.

Authors:  Michael Sonntag; Hans-Helmut König; Alexander Konnopka
Journal:  Pharmacoeconomics       Date:  2013-12       Impact factor: 4.981

4.  Is early intervention in psychosis cost-effective over the long term?

Authors:  Cathrine Mihalopoulos; Meredith Harris; Lisa Henry; Susy Harrigan; Patrick McGorry
Journal:  Schizophr Bull       Date:  2009-06-09       Impact factor: 9.306

Review 5.  A review of economic evaluations of health care for people at risk of psychosis and for first-episode psychosis.

Authors:  Gemma E Shields; Deborah Buck; Filippo Varese; Alison R Yung; Andrew Thompson; Nusrat Husain; Matthew R Broome; Rachel Upthegrove; Rory Byrne; Linda M Davies
Journal:  BMC Psychiatry       Date:  2022-02-17       Impact factor: 3.630

6.  Phase-based treatment versus immediate trauma-focused treatment in patients with childhood trauma-related posttraumatic stress disorder: study protocol for a randomized controlled trial.

Authors:  Noortje I van Vliet; Rafaele J C Huntjens; Maarten K van Dijk; Ad de Jongh
Journal:  Trials       Date:  2018-02-22       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.